PTO/SB/05 (11-00)
Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION **TRANSMITTAL**

0219US410 Attorney Docket No. Kim Vilbour Andersen First Inventor Protein C or Activated Protein C-Like Molecules

(Only for new nonprovisional applications under 37 CFR 1.53(b))

EF269992694US Express Mail Label No.

APPLICATION ELEMENTS				ADDRESS TO: U.S. Patent and Trademark Office PO Box 2327 - Box Patent Application				
See MPEP chapter 600 concerning utility patent application contents.				- ,		n, VA 2220		
2. (Submit an original and a Applicant claims see 37 CFR 1.27 Specification	[Total Pages 79]	CD-ROM or CD-R in duplicate, large table or Computer Program (<i>Appendix</i>) 8. Nucleotide and/or Amino Acid Sequence Submission (<i>if applicable, all necessary</i>) a Computer Readable Form (CRF)						
3.				b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. paper c. Statements verifying identity of above copies ACCOMPANYING APPLICATION PARTS 9. Assignment Papers (cover sheet & document(s)) 10. 37 CFR 3.73(b) Statement Power of Attorney 11. English Translation Document (if applicable) 12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 13. Preliminary Amendment 14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 15. Certified Copy of Priority Document(s) (if foreign priority is claimed)				
6. Application Data Sheet. See 37 CFR 1.76 or its equivalent. 17. Other:								
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation Divisional Continuation-in-part (CIP) Prior application information: Examiner Unknown Group Art Unit: 1744 For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.								
The incorporation can only be	relied upon when a portion has been in				applica	tion parts.		
Customer Number or Bar Code Label [Insert: Customer No. or Attach bar code label here] Or X Correspondence address below								
Name	Joanne R. Petithory							
	Maxygen, Inc.							
Address	515 Galveston Drive							
City Redwood City		Stat	e	California		Zip Code	94063	
Country USA Telept		Telephor	пе	650-298-530	0	Fax	650-298-5446	
Name (Print/Type)	Joanne R. Petithory		Registrati	ion No. (Attor	ney/Ag	ent)	42,995	
Signature	Jame R telil	LAU			Da	ate	11/29/01	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PTO/SB/17 (10-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

1	(\$)	1.	668
٠	~,	-,	~ ~ .

Complete if Known			
Application Number	Unassigned		
Filing Date	November 29, 2001		
First Named Inventor	Kim Vilbour Andersen		
Examiner Name	Unassigned		
Group Art Unit	Unassigned		
Attorney Docket No.	0219US410		

METHOD OF PAYMENT	FEE CALCULATION (continued)						
The Commissioner is hereby authorized to charge indicated fees and credit any overcomments to:	3. ADDITIONAL FEES						
indicated fees and credit any overpayments to: Deposit	Large Small						
Account 50-0990	Entity Entity Fee Fee Fee Fee Fee Description	E. Daid					
Number Deposit	Fee Fee Fee Fee Fee Description Code (\$) Code (\$)	Fee Paid					
Account Name Maxygen, Inc.	105 130 205 65 Surcharge - late filing fee or oath						
Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	127 50 227 25 Surcharge - late provisional filing fee or cover sheet						
Applicant claims small entity status.	139 130 139 130 Non-English specification						
See 37 CFR 1.27	147 2,520 147 2,520 For filing a request for ex parte reexamination						
2. Payment Enclosed:	112 920* 112 920* Requesting publication of SIR prior to						
Check Credit card Money Other	Examiner action						
FEE CALCULATION	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action						
1. BASIC FILING FEE	115 110 215 55 Extension for reply within first month						
Large Entity Small Entity	116 400 216 200 Extension for reply within second month						
Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	117 920 217 460 Extension for reply within third month						
101 740 201 370 Utility filing fee 740	118 1,440 218 720 Extension for reply within fourth month						
106 330 206 165 Design filing fee	128 1,960 228 980 Extension for reply within fifth month						
107 510 207 255 Plant filing fee	119 320 219 160 Notice of Appeal						
108 740 208 370 Reissue filing fee	120 320 220 160 Filing a brief in support of an appeal						
114 160 214 80 Provisional filing fee	121 280 221 140 Request for oral hearing						
740	138 1,510 138 1,510 Petition to institute a public use proceeding						
SUBTOTAL (1) (\$) 740	140 110 240 55 Petition to revive - unavoidable						
2. EXTRA CLAIM FEES Fee from	141 1,280 241 640 Petition to revive - unintentional						
Extra Claims below Fee Paid	142 1,280 242 640 Utility issue fee (or reissue)						
Total Claims 56 -20** = 36 X 18 = 648	143 460 243 230 Design issue fee						
Independent 3 - 3** = 0 x 84 = 0	144 620 244 310 Plant issue fee						
Multiple Dependent 280 = 280	122 130 122 130 Petitions to the Commissioner						
	123 50 123 50 Processing fee under 37 CFR 1.17(q)						
Large Entity Small Entity Fee Fee Fee Fee Description	126 180 126 180 Submission of Information Disclosure Stmt						
Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	581 40 581 40 Recording each patent assignment per property (times number of properties)						
102 84 202 42 Independent claims in excess of 3	146 740 246 370 Filing a submission after final rejection (37 CFR § 1.129(a))						
104 280 204 140 Multiple dependent claim, if not paid	149 740 249 370 For each additional invention to be						
109 84 209 42 ** Reissue independent claims over original patent	examined (37 CFR § 1.129(b))						
110 18 210 9 ** Reissue claims in excess of 20 and over original patent	179 740 279 370 Request for Continued Examination (RCE)						
	169 900 169 900 Request for expedited examination of a design application						
SUBTOTAL (2) (\$) 928	Other fee (specify)						
**or number previously paid, if greater; For Reissues, see above	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)	0					

SUBMITTED BY				Complete (if a)	Complete (if applicable)		
Name (Print/Type)	Joanne R. Petithory	Registration No. (Attorney/Agent)	42,995	Telephone	650-298-5300		
Signature	James Petith	ñu		Date	11/29/01		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.